Boehringer Files Pradaxa Antidote, Could Be First Reversible Novel Anticoagulant
This article was originally published in The Pink Sheet Daily
Executive Summary
Finishing off a rolling BLA, company believes that the specific antidote for its novel anticoagulant Pradaxa will be eligible for accelerated approval based on Phase I data in volunteers.
You may also be interested in...
Portola May Need Randomized Trial For AndexXa Approval. The Question Is When
Randomized trial represents higher bar for US approval of reversal agents for novel anticoagulants than expected – and if needed prior to approval, could delay AndexXa launch for two or maybe even four years.
Boehringer Avoids Pradaxa Trial, Board Chair Deposition With $650 Mil. Settlement
Settlement expected to resolve approximately 4,000 Pradaxa personal injury claims.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.